MedTrace Logo

Brolucizumab for CNV Associated With Pathologic Myopia

NCT04976244 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-03-24

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to pathologic myopia.

Conditions

  • Pathologic Myopia

Interventions

PROCEDURE

Intravitreal injection

Intravitreal injection to the regimen pro re nata

Sponsors & Collaborators

  • Odessa National Medical University

    collaborator OTHER

  • Mykolaiv Region Ophthalmogical Hospital

    collaborator OTHER

  • Central Polyclinic of Internal Affairs of Ukraine

    collaborator OTHER_GOV

  • Lesya Ukrainka Volyn National University

    collaborator OTHER

  • The Filatov Institute of Eye Diseases and Tissue Therapy

    lead OTHER

Principal Investigators

  • Andrii MD Korol, PhD · The Filatov Institute of Eye Diseases and Tissue Therapy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-04-01
Completion
2022-04-01

Countries

  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04976244 on ClinicalTrials.gov